MINT 1526A

Drug Profile

MINT 1526A

Alternative Names: MINT1526A

Latest Information Update: 03 Nov 2014

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Integrin alpha 5 beta 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 03 Sep 2014 Phase-I development is ongoing in USA
  • 01 Sep 2014 Genentech completes a phase I trial in Solid tumours in USA (NCT01139723)
  • 28 Jun 2010 Phase-I clinical trials in Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top